



MALDI-TOF MS based procedure to detect KPC-2 directly from positive blood culture bottles and colonies

Roque Figueroa-Espinosa^{a,b}, Agustina Costa^{a,c}, Daniela Cejas^{a,b}, Rubén Barrios^d, Carlos Vay^{a,e}, Marcela Radice^{a,b}, Gabriel Gutkind^{a,b,*}, José Di Conza^{a,b,*}

^a Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Argentina

^b CONICET, Argentina

^c ANPCyT, Argentina

^d BD Life Sciences, Argentina

^e Universidad de Buenos Aires, Hospital de Clínicas José de San Martín, Argentina



ARTICLE INFO

Keywords:

KPC-2
MALDI-TOF MS
Blood culture
Antimicrobial resistance detection

ABSTRACT

In this study, we identified specific carbapenemase-producing isolates applying an easy and rapid protocol for the detection of mature KPC-2 β -lactamase by MALDI-TOF MS from colony and positive blood culture bottles. In addition, we evaluated the correlation of the \sim 11,109 Da signal as a biomarker associated with KPC-2 production. A collection of 126 well-characterized clinical isolates were evaluated (including 60 KPC-2-producing strains). Presence of KPC-2 was assessed by MALDI-TOF MS on protein extracts. Samples were prepared using the double layer sinapinic acid technique. In order to identify mature KPC-2, raw spectra were analyzed focusing on the range between m/z 25,000–30,000 Da. A single distinctive peak, at approximately m/z 28,544 Da was found in all clinical and control KPC-2-producing strains, and consistently absent in the control groups (ESBL producers and susceptible strains). This peak was detected in all species independently of where the gene *bla*_{KPC-2} was embedded. Statistical results showed 100% sensitivity, CI95%: [94.0%; 100%] and 100% specificity, CI95%: [94.6%; 100%], indicating a promising test with a high discriminative power. KPC-2 β -lactamase could be directly detected from both colonies and blood culture bottles. On the other hand, the m/z 11,109 Da signal determinant was only associated with 32% of *Klebsiella pneumoniae* and *Escherichia coli* KPC positive isolates. This MALDI-TOF MS methodology has the potential to detect directly the widespread and clinically relevant carbapenemase, KPC-2, in *Enterobacterales* with a straightforward, low cost process, assuming MALDI-TOF MS is already adopted as the main identification tool, with clear clinical implications on antibiotic stewardship for early infection treatment.

1. Introduction

Resistance to carbapenems is one of the most relevant problems in current antimicrobial therapy for Gram-negative infections, limiting effective antimicrobial options and often leading to treatment failures (Ventola, 2015).

Class A carbapenemases are among the relevant resistance mechanisms in clinical isolates of *Enterobacterales*; KPC-2 is distributed in all continents, including community settings (van Duin and Doi, 2017). Coding genes for the major allelic variants of these β -lactamases are commonly carried on plasmids, with diversity being an important contributory factor for their spread (Cai et al., 2008; Giakkoupi et al., 2011; Gutkind et al., 2013; Navon-Venezia et al., 2006).

One of the key factors involving critical patients' survival is a timely decision for an effective treatment, as delays may reduce the survival chances as much as 10% daily (Luna et al., 2006). Therefore, among WHO recommendations, improvement (and acceleration) of diagnostic procedures is clearly needed (as an example, a dedicated call for better diagnosis is requested by the EU (<https://www.jpiamr.eu/coming-soon-call-for-diagnostics-and-surveillance-africa-and-asia/>)). So, rapid and specific methods for carbapenemase detection in clinical microbiology are desirable in order to avoid treatment failure and prevent dissemination events (Rhodes et al., 2017).

Nowadays, preliminary screening for carbapenemase producers in clinical specimens is based on phenotypic tests. Traditional microbiological methods such as double disk synergy tests using β -lactam and

* Corresponding authors at: Laboratorio de Resistencia Bacteriana, Facultad de Farmacia y Bioquímica (UBA), Junín 956, 8vo. Piso, CP 1113 Ciudad Autónoma de Buenos Aires, Argentina.

E-mail addresses: ggutkind@ffyb.uba.ar (G. Gutkind), jdiconza@ffyb.uba.ar (J. Di Conza).

<https://doi.org/10.1016/j.mimet.2019.02.020>

Received 14 November 2018; Received in revised form 25 February 2019; Accepted 28 February 2019

Available online 05 March 2019

0167-7012/ © 2019 Elsevier B.V. All rights reserved.

β -lactamase-inhibitor disks, growth-based assays like modified Hodge test, and even the epsilometer tests (*E*-tests), remain convenient, easy to perform, but not fast methods for detecting these β -lactamase in Gram-negative bacilli (around 24–48 h after microorganism isolation). Manual and automated determination of minimal inhibitory concentration (broth microdilution assay and Phoenix or VITEK, respectively) are also reliable methods. Besides being time-consuming, some traditional microbiological methods have disadvantages such as interpretation difficulty and variability in the sensitivity/specificity parameters among different species (AlTamimi et al., 2017).

Other phenotype-based assays are available, including, immunochromatographic assays (ICAs) and rapid colorimetric-based tests (commercial versions of the Carba NP, CNPt-Direct, and Blue-Carba) (Lima-Morales et al., 2018; Nordmann et al., 2012; Wareham et al., 2018). Also, polymerase chain reaction (PCR) used to confirm the presence of these resistance markers, is quite expensive (Mirande et al., 2015) and requires at least 3 h to obtain the results.

One approach that may shorten the time-to-result for antibiotic susceptibility testing is matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF MS). Incorporation of MALDI-TOF MS has been one of the most significant breakthrough technologies included in modern clinical microbiology, and is today routinely used in medium and high complexity laboratories for rapid species identification (Sandalakis et al., 2017).

Current studies demonstrate the possibility to apply a MALDI-TOF MS approach to predict β -lactamase production based on the detection of hydrolyzed β -lactam substrates. Although reliable, this detection is laborious. β -lactam hydrolysis is evaluated after at least one hour incubation of the bacteria in presence of a suitable substrate (Hooff et al., 2012; Oviano et al., 2016; Sparbier et al., 2012). Following this procedure, enzyme detection is feasible and reflects the presence of one or more enzymes with hydrolytic activity on the provided substrate.

Direct detection of a specific enzyme by analysis of the MALDI-TOF MS generated protein profile has been the subject of research in different studies. Among them, Papagiannitsis et al. detected CMY-2 enzyme in different enterobacteria after extraction of periplasmic proteins using a multiple steps procedure (Hart et al., 2015; Papagiannitsis et al., 2014). More recently, Espinosa et al. could detect a peak corresponding to CMY-2, analyzing the spectrum of proteins directly obtained from cellular lysates of *Escherichia coli* and other enterobacteria which displayed resistance to third generation cephalosporins (Espinosa et al., 2018).

Antibiotic resistance has also been predicted by MALDI-TOF MS by detection of biomarkers associated with a specific resistance determinant. The p019 protein, linked to the plasmid located Tn4401a, present in KPC-2 producing *Klebsiella pneumoniae* ST 258, can be detected as a 11,109-Da peak in MALDI-TOF MS and was used to predict KPC carbapenemase producers (Centonze et al., 2018; Gaibani et al., 2016; Youn et al., 2016). Thus, prediction of this marker depends upon the surrounding genetic context, and as epidemiology of endemic or hyperendemic clones may vary across time and regions, detection of mature β -lactamase by MALDI-TOF MS, directly associated with the resistance pattern of bacteria, could be considered a more reliable marker.

Enterobacteriales may account for up to 30% bloodstream infections (Tariq and Rasool, 2016). As reported by Kumar et al., if an ineffective treatment is applied in patients with septic shock, the mean survival rate decreased 7.6% per hour delayed (Kumar et al., 2006). The development of more rapid techniques for the prompt and accurate detection of resistance markers in the clinical laboratory should guide appropriate treatments.

The aim of this study was to apply an easy and quick methodology for the detection of mature KPC-2 β -lactamase by MALDI-TOF MS directly on Gram-negative bacilli, focusing on *Enterobacteriales*. In addition, the correlation of the ~11,109 Da signal as a biomarker associated with the KPC-2 production was evaluated and the possibilities for direct

KPC-2 detection from positive blood culture bottles by MALDI-TOF MS were analyzed.

2. Materials and methods

2.1. Control strains

Recombinant and transformant strains expressing KPC-2 were used as controls.

To construct the recombinant plasmid, full-length *bla*_{KPC-2} (882 bp) was amplified by PCR using custom designed primers KPC-2F (5'-TAC GCGTCGACATGTCTACTGTATCGCCGTC-3') and KPC-2R (5'-CCGGAAT TCTTACTGCCCGTTGACGCC-3') containing *Sal*I and *Eco*RI restriction sites, respectively. The *Sal*I–*Eco*RI *bla*_{KPC-2} fragment was cloned into the pK19 vector (recombinant plasmids pKPC-2-4), transformed in *E. coli* TOP10 (*E. coli* TOP10/pKPC-2-4) and selected on Tryptic Soy Agar (TSA) containing 1 μ g/ml imipenem (Sigma-Aldrich, USA). Recombinant plasmid was confirmed by sequencing.

A wild-type plasmid carrying the *bla*_{KPC-2} and *bla*_{CTX-M-14} genes obtained from a clinical isolate (TFI-KPC) was electroporated into electrocompetent *E. coli* XL1-blue cells. *E. coli* *bla*_{KPC}-positive transformant strains were selected on Mueller Hinton (MH) (Britania, Argentina) agar plates containing 1 μ g/ml meropenem (Sigma-Aldrich).

The MALDI-TOF MS spectra range to detect the KPC-2 enzyme was specially focused in the range between *m/z* 25,000–30,000 Da based on the theoretical mass of mature KPC-2 protein.

2.2. Strain collection

A panel of 126 previously characterized isolates deposited in our laboratory collection in Buenos Aires, Argentina, was used. There was no epidemiological link among them. All bacteria were identified by MALDI-TOF MS (Bruker Daltonics, Germany) following the standard procedure (Matsuda et al., 2012). Sixty KPC-2-producing clinical isolates (*Klebsiella pneumoniae* (39), *Enterobacter cloacae* (7), *Escherichia coli* (4), *Serratia marcescens* (4), *Citrobacter braakii* (1) and *Pseudomonas aeruginosa* (5)) and 66 KPC-2-negative isolates were included. In addition to being the most commonly isolated species, the KPC-2-producing *K. pneumoniae* isolates also corresponded to multiple different ST that were circulating in our region (Tables 1 and 2).

2.3. Antimicrobial susceptibility and genetic characterization

All isolates were previously characterized phenotypically by disk diffusion and synergy tests according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2018). Production of carbapenemases was investigated using boronic acid and EDTA by synergy tests (Lee et al., 2001; Tsakris et al., 2009). Further genotypic characterization was carried out by PCR focused on different β -lactamase gene families. PCR amplifications were performed on total DNA using primers and conditions described previously (Dominguez et al., 2018). Amplicons were sequenced on both strands using an ABI3730XL DNA sequencer (Tables 1 and 2).

2.4. Bacterial typing

K. pneumoniae ST-258 clone was characterized by the *pilV-l* PCR amplification (Adler et al., 2014) while other STs were determined by the multilocus sequence typing (MLST) scheme (Diancourt et al., 2005). Characterization of the O25b-ST131 clone of *E. coli* was also done by allele-specific PCR assay based on detection of the *pabB* gene (Clermont et al., 2009). The genetic environment of the *bla*_{KPC-2} gene (isoforms of Tn4401) was explored by mapping as described previously (Cuzon et al., 2010; Kitchel et al., 2009; Naas et al., 2008) (Table 1). In order to evaluate the presence of the *p019* gene (which encodes for a hypothetical protein named p019) in the *bla*_{KPC}-producing strains, a simple PCR

Table 1
Characterization of KPC-2 producing strains.

Strain	Isolate Origin	Resistance Marker	Peak at m/z ~28,477 Da	Peak at m/z ~11,109 Da	p019 gene	KPC element (Tn4401)	Sequence Type (ST)
<i>K. pneumoniae</i> 720	Human/Urine	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 952	Human/Urine	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 729	Human/Tracheal fluid	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 139	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 439	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 176	Human/Swab	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 791	Human/Swab	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-15} / <i>bla</i> _{TEM-1a} / <i>bla</i> _{OXA-1} / <i>bla</i> _{SHV-11}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 069	Human/Abdominal fluid	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 070 ^{BC}	Human/Liver abscess	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> 805	Human/Urine	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	340
<i>K. pneumoniae</i> UT1-7	Human/Blood	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-15} / <i>bla</i> _{TEM-1b} / <i>bla</i> _{SHV-11}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> 741 ^{BC}	Human/BAL	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>K. pneumoniae</i> 197 ^{BC}	Human/Swab	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>K. pneumoniae</i> CX27	Human/Urine	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	11
<i>K. pneumoniae</i> HJMC5 ^{BC}	Human/Soft tissue	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> HSM 456	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	25
<i>K. pneumoniae</i> A12 ^{BC}	Human/Tracheal fluid	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	SLV 13
<i>K. pneumoniae</i> A24 ^{BC}	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M}	(+)	(–)	(–)	Yes ^b	258
<i>K. pneumoniae</i> A23	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	SLV 13
<i>K. pneumoniae</i> A25	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M}	(+)	(–)	(–)	Yes ^b	258
<i>K. pneumoniae</i> A27	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M}	(+)	(–)	(–)	Yes ^b	258
<i>K. pneumoniae</i> M1	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M2	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> M3	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	13
<i>K. pneumoniae</i> M4	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M5	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M6	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	101
<i>K. pneumoniae</i> M7	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> M9 ^{BC}	Human/Soft tissue	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M10	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M14 ^{BC}	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> M15 ^{BC}	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> M17	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	392
<i>K. pneumoniae</i> M22	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	Yes ^b	307
<i>K. pneumoniae</i> M23	Human/Abdominal fluid	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> 2–10	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> 16–10	Human/BAL	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> 19–10	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>K. pneumoniae</i> 20–10	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(+)	(+)	Yes ^a	258
<i>E. cloacae</i> 680 ^{BC}	Human/Urine	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G1}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> A26	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G9}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> 016	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> 043	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> 21,051	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> 029	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. cloacae</i> 91,051	Human/Swab	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. coli</i> 519	Human/Soft tissue	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G9}	(+)	(+)	(+)	Yes ^a	131
<i>E. coli</i> 151 ^{BC}	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	131
<i>E. coli</i> 547	Human/Soft tissues	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-G9}	(+)	(+)	(+)	Yes ^a	131
<i>E. coli</i> 075 ^{BC}	Human/Peritoneal fluid	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	131
<i>S. marcescens</i> AMP162-I ^{BC}	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>S. marcescens</i> AMP162-II	Human/Catheter	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>S. marcescens</i> Sm759 ^{BC}	Human/Blood	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>S. marcescens</i> Sm216 ^{BC}	Human/Tracheal fluid	<i>bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>C. braakii</i> Cbra007 ^{BC}	Human/Urine	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>P. aeruginosa</i> 2047	Human/ Nosocomial	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	654
<i>P. aeruginosa</i> 4270	Respiratory secretions	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	654
<i>P. aeruginosa</i> 4753	Respiratory secretions	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	654

(continued on next page)

Table 1 (continued)

Strain	Isolate Origin	Resistance Marker	Peak at <i>m/z</i> ~28,477 Da	Peak at <i>m/z</i> ~11,109 Da	<i>p019</i> gene	KPC element (Tn4401)	Sequence Type (ST)
<i>P. aeruginosa</i> Mart1	Human/ Nosocomial	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>P. aeruginosa</i> 537	Human/ Nosocomial	<i>bla</i> _{KPC-2}	(+)	(–)	(–)	NTE _{KPC}	ND
<i>E. coli</i> DH5α	Laboratory Strain	<i>gyrA96</i>	(–)	(–)	(–)	(–)	n/a
<i>E. coli</i> TFI-KPC (Tc)	Laboratory Strain	<i>gyrA96/bla</i> _{KPC-2} / <i>bla</i> _{CTX-M-9}	(+)	(+)	(+)	Yes ^a	n/a
<i>E. coli</i> TOP10	Laboratory Strain	<i>rpsL</i>	(–)	(–)	(–)	(–)	n/a
<i>E. coli</i> TOP10 + pk19	Laboratory Strain	<i>rpsL/aph(3')-Ia</i>	(–)	(–)	(–)	(–)	n/a
<i>E. coli</i> TOP10 + pKPC-2-4 (RC)	Laboratory Strain	<i>bla</i> _{KPC-2} / <i>rpsL/aph(3')-Ia</i>	(+)	(–)	(–)	(–)	n/a

NTE_{KPC}: *bla*_{KPC}-bearing partial or non-Tn4401 element.

^{BC} Blood Culture assay strains, *bla*_{CTX-M-G1}, *bla*_{CTX-M-G2} and *bla*_{CTX-M-G9}; correspond to *bla*_{CTX-M} gene group 1, 2 or 9, respectively, SLV: single locus variant, ND: Not determined, n/a: not applicable.

^a Tn4401a isoform.

^b Tn4401 isoform different to Tn4401a.

was performed using custom designed primers (p019F: 5'- AATATTG ATACTGACCGC-3' and p019R: 5'- AACCCATTTTGCATCTG-3') which rendered an amplicon of 328 bp.

2.5. Protein extraction protocol for β-lactamase detection by MALDI-TOF MS

Pure cultures were obtained on MH agar plates without antibiotics and incubated overnight at 37 °C. Samples were prepared using a modified extraction protocol for β-lactamase detection (formic acid-isopropyl alcohol – water, 17:33:50 ratio by volume), as previously described (Espinosa et al., 2018).

2.6. Detection of mature KPC-2 protein from colonies

The protein extraction with an organic solvent mentioned above was performed on colonies. The samples were loaded once in three different spots on the stainless steel MALDI target plate using the double layer sinapinic acid technique. Every spot was measured in duplicate (6 spectra per sample). Mass spectra were obtained using a Microflex LT mass spectrometer by flexControl 3.4 software (Bruker Daltonics, Germany) within the mass range of 17,000 to 50,000 Da as previously described (Espinosa et al., 2018). Data were automatically acquired using the AutoXecute acquisition control software (Bruker Daltonics) and spectra were analyzed using flexAnalysis 3.4 software.

2.7. Detection of hypothetical p019 protein (~11,109 Da peak) by MALDI-TOF MS

Detection of the ~11,109 Da peak was carried out in the 2000–20,000 Da range for all 126 isolates. Briefly, 1 μl of the protein extraction for β-lactamase detection was applied in triplicate onto a MALDI target, the dried spots were overlaid with 1 μl of HCCA matrix (10 mg/ml α-cyano-4-hydroxy-cinnamic acid) (Bruker Daltonics) and acquired twice for a total of six spectra (Centonze et al., 2018; Youn et al., 2016). An external Standard BTS (Bruker Daltonics) was used for mass calibration during parameter optimization. Spectra were generated on a Microflex LT (Bruker Daltonics) MALDI-TOF MS system operated in linear mode with a total of 240 laser shots. Data acquisition and further analysis were performed as detailed above after baseline subtraction.

2.8. Detection of KPC-2 from blood culture (BC) bottles using MALDI-TOF MS

Direct KPC-2 detection from positive blood culture bottles was performed on 39 samples: 16 KPC-2-producing clinical isolates of *K. pneumoniae* (9), *E. cloacae* (1), *E. coli* (2), *S. marcescens* (3), and *C.*

braakii (1); 23 non-KPC-2 producing clinical isolates were also included (Table 1). Briefly, 1 ml of a bacterial suspension (approximately 10⁴ CFU) was inoculated in a pediatric blood culture bottle (BD BACTEC™ Peds Plus™/F Culture Vials, Argentina) previously inoculated with 5 ml of human blood. Blood cultures were incubated at 37 °C for 18 h. Direct KPC-2 detection was carried out using the protocol previously described (Espinosa et al., 2018). An extra-washing step with distilled water on the pellet was added prior to solvent extraction in order to remove cell debris. Samples were tested in triplicate using the double layer sinapinic acid technique as described above.

2.9. Statistical analysis

Spectra of each strain after automatic calibration and normalization were analyzed with the software ClinProTools 3.0 (Bruker Daltonics) (Ketterlinus et al., 2005). Statistical analysis was performed using the full raw spectra (17,000 to 50,000 Da) with the “Peak Statistic Calculation” tool. The area under the curve (AUC) of the ROC curve was evaluated for the specific peak (28,544 Da) between KPC-2 positive and negative strains, to establish the sensitivity, specificity and the discriminative power.

2.10. Detection index

The detection index (DI) was calculated for each isolate taking into account the peak intensities at 28,544 Da (PI_{28544 Da}) as follows: DI = [PI_{28544 Da} mean for each clinical isolate/PI_{28544 Da} mean of 31 spectra of *E. coli* ATCC 25922]. *E. coli* ATCC 25922 spectra were used as the negative control. Data that did not follow a normal distribution, were presented as median and interquartile range. Also, 95% confidence intervals (CI95%) were calculated. Comparisons between groups were performed using the Mann-Whitney test (GraphPad Prism Version 5).

3. Results and discussion

The MALDI-TOF MS spectra range to detect the KPC-2 enzyme was modified, from the bacterial identification range, to 17,000–50,000 Da, specially focusing on the range between *m/z* 25,000–30,000 Da. *E. coli* TOP10 carrying the recombinant plasmid pK19-KPC-2 (called pKPC-2-4) and their corresponding controls (*E. coli* TOP10 and *E. coli* TOP10 + pK19) were processed. A characteristic peak at around 28,544 Da (slightly differing from the expected value for the mature KPC-2 enzyme, i. e. without signal peptide, 28,477 Da) was only observed in the recombinant pKPC-2-4 strain (Fig. 1a). In addition, the KPC-2 producing *E. coli* DH5α (electroporant) called TFI-KPC, displayed the same characteristic peak which was absent in the isogenic strain (*E. coli* DH5α) (Fig. S1). These KPC-2-producing strains were used as

Table 2
Characterization of non KPC-2 producing strains.

Strain	Isolate Origen	Resistance Marker	Peak at m/z ~28,477 Da	Peak at m/z ~11,109 Da	Sequence Type (ST)
<i>K. pneumoniae</i> I26 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-G9}	(–)	(–)	ND
<i>K. pneumoniae</i> HAP13	Human/Urine	<i>bla</i> _{CTX-M-G2}	(–)	(–)	ND
<i>K. pneumoniae</i> HAP33	Human/Urine	<i>bla</i> _{CTX-M-G1}	(–)	(–)	ND
<i>K. pneumoniae</i> HAP121	Human/Urine	<i>bla</i> _{CTX-M-G1}	(–)	(–)	ND
<i>K. pneumoniae</i> B4	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> CM4	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> I3 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> I4	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> I11	Human/Nosocomial	<i>bla</i> _{CTX-M-G1}	(–)	(–)	ND
<i>K. pneumoniae</i> I17 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-G1}	(–)	(–)	ND
<i>K. pneumoniae</i> I21 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-G1}	(–)	(–)	ND
<i>K. pneumoniae</i> T8	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> C14 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> I18 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> N1	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> C10 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> CV1 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2} / <i>bla</i> _{CTX-M-15}	(–)	(–)	11
<i>K. pneumoniae</i> CM1	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	11
<i>K. pneumoniae</i> I1	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> N2 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>K. pneumoniae</i> Ck ^{BC}	Human/Nosocomial	<i>bla</i> _{CMY-2}	(–)	(–)	ND
<i>E. coli</i> CM3	Human/Nosocomial	<i>bla</i> _{CTX-M-14}	(–)	(–)	ND
<i>E. coli</i> N8	Human/Nosocomial	<i>bla</i> _{CTX-M-14}	(–)	(–)	ND
<i>E. coli</i> C17 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-14}	(–)	(–)	ND
<i>E. coli</i> SM8	Human/Nosocomial	<i>bla</i> _{CTX-M-14}	(–)	(–)	68
<i>E. coli</i> L4 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	131
<i>E. coli</i> M1	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	410
<i>E. coli</i> N2	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	ND
<i>E. coli</i> N4	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	410
<i>E. coli</i> SM5 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	131
<i>E. coli</i> T3	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	131
<i>E. coli</i> T1	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	131
<i>E. coli</i> V91	Pet/Cat	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> V109	Pet/Cat	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> 24–28 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> N1 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> Itu2	Human/Urine	<i>bla</i> _{CTX-M-2} , <i>mcr-1</i>	(–)	(–)	ND
<i>E. coli</i> N14	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> SM3	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
<i>E. coli</i> VTEM-38	Pet/Dog	<i>bla</i> _{TEM-1}	(–)	(–)	ND
<i>E. coli</i> VTEM-86	Pet/Dog	<i>bla</i> _{TEM-1}	(–)	(–)	ND
<i>E. coli</i> IACA17	Human/Urine	NDβ	(–)	(–)	ND
<i>E. coli</i> CEM4	Human/Urine	NDβ	(–)	(–)	ND
<i>E. coli</i> 1510	Human/Urine	<i>bla</i> _{CMY-2}	(–)	(–)	ND
<i>E. coli</i> 856	Human/Abdominar fluid	<i>bla</i> _{CMY-2}	(–)	(–)	ND
Cbra CX16 ^{BC}	Human/Soft tissue	NDβ	(–)	(–)	ND
Cbra HdeC2 ^{BC}	Human/Urine	NDβ	(–)	(–)	ND
Sm I2 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
Sm T9 ^{BC}	Human/Nosocomial	<i>bla</i> _{CTX-M-2}	(–)	(–)	ND
Sm 947 ^{BC}	Human/ND	<i>bla</i> _{SME-1}	(–)	(–)	ND
Sm CAR653	Human/Soft tissue	NDβ	(–)	(–)	ND
Sm CX46	Human/Soft tissue	NDβ	(–)	(–)	ND
Sm CX17 ^{BC}	Human/Soft tissue	NDβ	(–)	(–)	ND
Sm HdeC30	Human/Tracheal fluid	NDβ	(–)	(–)	ND
Sm HAP54	Human/Bile	NDβ	(–)	(–)	ND
Sm SOA15	Human/Blood	NDβ	(–)	(–)	ND
Sm VSm102	Pet/Dog	NDβ	(–)	(–)	ND
Sm VSm117	Pet/Dog	NDβ	(–)	(–)	ND
Ecl 1042 ^{BC}	Human/Blood	<i>act7</i> / <i>bla</i> _{TEM-1}	(–)	(–)	ND
Ecl I28	Human/Nosocomial	<i>bla</i> _{CTX-M-15}	(–)	(–)	ND
Ecl V206	Pet/Cat	Ind AmpC	(–)	(–)	ND
Ecl V211	Pet/Cat	NDβ	(–)	(–)	ND
Ecl V207 ^{BC}	Pet/Dog	<i>bla</i> _{CTX-M-15}	(–)	(–)	ND
<i>P. aeruginosa</i> 24	Human/Nosocomial	NDβ	(–)	(–)	ND
<i>P. aeruginosa</i> 2054	Human/Nosocomial	NDβ	(–)	(–)	ND
<i>P. aeruginosa</i> ATCC 9027	Laboratory Strain	NDβ	(–)	(–)	ND

^{BC} Blood Culture assay strains, *bla*_{CTX-M-G1}, *bla*_{CTX-M-G2} and *bla*_{CTX-M-G9}: correspond to *bla*_{CTX-M} gene group 1, 2 or 9, respectively, NDβ: Non-detectable β-lactamases, Ind: Inducible β-lactamase, ND: Not determined.

positive controls each time when the different clinical isolates were analyzed.

The protein extraction protocol for β-lactamase detection was conducted for all 126 collection isolates included in the study. To confirm

bacterial identification these extracts were assessed by MALDI-TOF MS using the standard procedure. Subsequently, all the protein extracts were analyzed by MALDI-TOF MS in order to detect the presence of KPC-2. Comparison among mass spectral profiles showed that two




Fig. 1. Peaks of MALDI-TOF mass spectra of the KPC-2 and non-KPC-2 producing strain. a) Peak detection of $\sim 28,544$ Da in *E. coli* with recombinant plasmid (*E. coli* TOP10 + pKPC-2-4) is indicated by red line; Absence of the $\sim 28,544$ - m/z peak in the recipient strain (*E. coli* TOP10 + pK19) is indicated by green line. Peak corresponding to KPC-2 is indicated with arrows. b) Spectra show the presence or absence of the KPC-2 peak in different *Enterobacteriales*. Specific colour (red, blue, light blue, magenta, and violet) was assigned to particular species (*K. pneumoniae*, *E. cloacae*, *E. coli*, *S. marcescens*, and *C. braakii* respectively). Green spectra correspond to non-KPC-2-producing strains (susceptible to β -lactams or TEM-1-, CMY-2- or CTX-M- producers). c) Dark blue spectra correspond to KPC-2 producing *P. aeruginosa* and green correspond to non-KPC-2-producing *P. aeruginosa*. d) Box plot showing median and interquartile range is calculated from the intensities of the 28,544 Da peak in the KPC-2 and non-KPC-2 producing strains (red and green box, respectively). x and y axes show m/z values and intensity (in arbitrary units – a.u.), respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

groups could be differentiated after peak analysis. A single distinctive peak with different intensities, at approximately m/z 28,544 Da was found in all previously characterized KPC-2-producing *Enterobacteriales* and was consistently absent in the KPC-2 negative isolates (Fig. 1b). The presence of this distinctive peak was also observed in KPC-2-producing isolates of *P. aeruginosa* (Table 1 and Fig. 1c). Analysis of replicate cultures of all isolates gave consistent and straightforward mass spectral profiles within this range.

Thus, the visualization and identification of the 28,544 Da peak corresponding to the KPC-2 mature protein was successful using the supernatant obtained after applying the extraction protocol for β -lactamase detection (formic acid, isopropyl alcohol, water).

Statistical results showed a p -value $< .000001$ by Anderson-Darling test and Wilcoxon/Kruskal-Wallis test which confirmed a significant difference for the $\sim 28,544$ Da peak when both groups were compared (KPC-2 positive vs KPC-2 negative isolates) (Fig. 1d). Consistently, the area under the curve (AUC) of the ROC curve for this specific peak was 1 (100% sensitivity, CI95%: [94.0%; 100%]) and 100% specificity, CI95%: [94.6%; 100%]). It should be noted that representative isolates of the main *K. pneumoniae* sequence types which are disseminated worldwide were included (such as ST258, ST307, ST25, ST11, ST392, ST340, ST101, ST13) suggesting that this peak detection may be effective on different strains. Furthermore, the $\sim 28,544$ Da peak detection was useful on different species where KPC-2 is less frequent.

The DI of KPC-2-producing isolates from colony assays varied between 171.3 and 12.0 (median: 33.0, CI95%: [26.1; 39.9]) while for negative strains, between 5.0 and 0.2 (median: 1.5, CI95%: [1.2; 1.7])

(Fig. 2a). Values of this parameter could be used to define a cut-off if it were possible to implement an automated procedure for the detection of clinically relevant β -lactamases.

Only eleven out of 39 KPC-2-producing *K. pneumoniae* (28%) were positive for the $\sim 11,109$ Da peak and all of them were also positive for the *p019* gene by PCR. All of these 11 strains showed the presence of Tn4401 element corresponding to isoform a, and 10/11 (91%) belonged to ST258 which was identified extensively worldwide (Table 1). The peak of $\sim 11,109$ Da was not observed in the rest of KPC-2 producing *K. pneumoniae* isolates (72%, 28/39). Four out of 28 isolates had Tn4401 (not isoform a) and three out of those four corresponded to the ST258 (Table 1). In the remaining isolates, *bla*_{KPC-2} was associated with a truncated structure of this transposon or to a non-Tn4401 element (NTE).

Of the four KPC-2-producing *E. coli* clinical isolates (all characterized as ST131), two were positive for the $\sim 11,109$ Da peak coinciding with the presence of the *p019* gene in the latter. As expected, Tn4401 (isoform a) was also detected in these two strains (Table 1). The remaining KPC-2 positive species (*E. cloacae*, *S. marcescens*, *C. braakii* and *P. aeruginosa*) gave negative results for the $\sim 11,109$ Da peak, *p019* gene and Tn4401. In these cases, *bla*_{KPC-2} would be associated with an NTE (Table 1).

Detection of the $\sim 11,109$ Da peak was considered a promising test for the rapid detection of KPC-2-producing strains by MALDI-TOF MS (Gaibani et al., 2016; Youn et al., 2016). In our study, the *bla*_{KPC-2} environment in the circulating strains showed a low prevalence of the *p019* gene. This is not surprising considering that different genetic




Fig. 2. Box and whisker plot showing DI of KPC-2-producing strains (red) and non KPC-2-producing strains (green) (GraphPad Prism). The box always extended from the 25th to 75th percentiles. The line in the middle of the box is plotted at the median. The whiskers are drawn down to the 5th percentile and up to the 95th. Points below and above the whiskers – outliers – are drawn as individual points. *p*-value obtained with Mann-Whitney test shows a significant difference between the two groups. a) Box-plot of DI from colony analysis. b) Box-plot of DI from blood culture bottle analysis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

platforms can replace Tn4401, and the rearrangements that often occur in plasmids leads to the genetic evolution of these strains and the emergence of several successful clones. As previously reported, the *p019* gene is part of the insertion sequence IS*Kpn31* which is inserted or is a constituent of the Tn4401a (Centonze et al., 2018). In this study, *bla*_{KPC-2} was not always associated with the Tn4401a isoform and was frequently associated with different environments. In good agreement with our results, previous research has also revealed that strains circulating in different regions possess various KPC environments (Partridge, 2014; Stoesser et al., 2017). Thus, the protein p019 or its gene should be considered a biomarker with low sensitivity in our region and others where the KPC-2 gene is embedded in diverse surrounding environments.

In good agreement with our previous results, the distinctive peak of ~28,544 Da, corresponding to KPC-2 was visually observed in all spectra of KPC-2-producing isolates in the blood culture bottles tested, but not in the carbapenem-susceptible strains (Fig. S2a). In order to validate this methodology in the clinical setting and estimate if the biomass present at the time the blood culture becomes positive allows for sufficient KPC-2 detection, a trial with the participation of different laboratories will be necessary. Statistical results showed a 100% sensitivity and specificity (AUC: 1) (Fig. S2b) with all included strains under the assayed conditions. Moreover, when the DI was evaluated in the blood culture bottles assays, KPC-2-producing isolates ranged between 118.1 and 9.3 (mean: 47.3, CI95%: [31.2; 63.4]) and the KPC-negative isolates between 2.4 and 0.1 (mean: 1.0, CI95%: [0.6; 1.2]) (Fig. 2b). Presence of the biomarker (~11,109 Da peak) was also assessed directly from the blood culture bottles and it was detected only in the p019 positive isolates (3/16).

One of the advantages of the use of MALDI-TOF MS for KPC-2 detection from colony or blood culture bottle is the substantial decrease in the turnaround time (TAT) compared to automated and traditional microbiological phenotypic methods. Although β -lactamase detection by ICAs display a shorter TAT (Riccobono et al., 2018) than MALDI-TOF MS resistance detection, the latter is a low cost procedure once the technology is in place (Tran et al., 2015).

At the present time, any β -lactamase activity can be predicted using MALDI-TOF MS by detection of hydrolysis products of β -lactams. However, it is not possible to establish an accurate resistance profile, unless complementary hydrolysis tests with several substrates requiring 1 h incubation time each are performed (Hooff et al., 2012; Sparbier et al., 2012). In this sense, the characterization of the resistance marker that is achieved with our protocol could be considered as another advantage. It is important to highlight that, beyond KPC-2, the procedure used in this work proved to be useful for the detection of different β -lactamases such as CMY-2 (Espinosa et al., 2018) and preliminarily on different CTX-Ms (Figueroa et al. 28th ECCMID, 2018).

It is well known that colorimetric tests are easy to perform and cost-

effective methods but, in contrast with our method, the identification of β -lactamases involved is not possible.

Applying the proposed protocol using a single sample preparation method it was possible to carry out the bacterial identification (even the p019 resistance biomarker) and detection of KPC production, in < 1 h (usually 30 min), employing the HCCA and SA matrices, respectively.

4. Conclusions

In this study, we demonstrated that MALDI-TOF MS is able to detect directly the most clinically relevant carbapenemase, the KPC-2-enzyme, on different Gram-negative bacilli, mainly *Enterobacteriales*, both from colony material and directly from positive blood culture bottles, and at the same time that bacterial identification becomes available. The rapid and accurate detection of KPC-2, as well as any other relevant β -lactamase that are still being explored by MALDI-TOF and other techniques might have extensive clinical implications in resistance diagnosis, antibiotic stewardship for early infection treatment, and implementation of procedures aimed at carbapenem resistance containment.

Acknowledgements

The authors would like to thank V. Rumi and M. Marchisio for providing some strains, and C. Barberis for her technical support. In addition, we thank D. Assis (Bruker Daltonics) for his invaluable assistance facilitating the software access to analyze the spectra.

Funding

This work was supported by Agencia Nacional de Promoción Científica y Tecnológica PICT 1925–2015 to GG.

Transparency declarations

None to declare.

Conflicts of interest

The authors declare that they have no conflicts of interest

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mimet.2019.02.020>.

References

Adler, A., Khabra, E., Chmelnitsky, I., Giakkoupi, P., Vatopoulos, A., Mathers, A.J., Yeh,

- A.J., Sifri, C.D., De Angelis, G., Tacconelli, E., Villegas, M.V., Quinn, J., Carmeli, Y., 2014. Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing *Klebsiella pneumoniae* clone. *Diagn. Microbiol. Infect. Dis.* 78, 12–15. <https://doi.org/10.1016/j.diagmicrobio.2013.10.003>.
- Altamimi, M., AlSalamah, A., AlKhulaifi, M., AlAjlan, H., 2017. Comparison of phenotypic and PCR methods for detection of carbapenemases production by Enterobacteriaceae. *Saudi J. Biol. Sci.* 24, 155–161. <https://doi.org/10.1016/j.sjbs.2016.07.004>.
- Cai, J.C., Zhou, H.W., Zhang, R., Chen, G.X., 2008. Emergence of *Serratia marcescens*, *Klebsiella pneumoniae*, and *Escherichia coli* isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. *Antimicrob. Agents Chemother.* 52, 2014–2018. <https://doi.org/10.1099/jmm.0.000831>.
- Centonze, A.R., Bertocelli, A., Savio, C., Orza, P., Bedenic, B., Mazzariol, A., 2018. Evaluation of rapid KPC carbapenemase detection method based on MALDI-TOF VITEK MS spectra analysis. *J. Med. Microbiol.* <https://doi.org/10.1099/jmm.0.000831>.
- Clermont, O., Dhanji, H., Upton, M., Gibreel, T., Fox, A., Boyd, D., Mulvey, M.R., Nordmann, P., Ruppe, E., Sarthou, J.L., Frank, T., Vimont, S., Arlet, G., Branger, C., Woodford, N., Denamur, E., 2009. Rapid detection of the O25b-ST131 clone of *Escherichia coli* encompassing the CTX-M-15-producing strains. *J. Antimicrob. Chemother.* 64, 274–277. <https://doi.org/10.1093/jac/dkp194>.
- CLSI, 2018. Performance standards for antimicrobial susceptibility testing. In: *Twenty-eighth Informational Supplement M100. USACLSI*, Wayne, PA 2018.
- Cuzon, G., Naas, T., Truong, H., Villegas, M.V., Wisell, K.T., Carmeli, Y., Gales, A.C., Venezia, S.N., Quinn, J.P., Nordmann, P., 2010. Worldwide diversity of *Klebsiella pneumoniae* that produce beta-lactamase bla_{KPC-2} gene. *Emerg. Infect. Dis.* 16, 1349–1356. <https://doi.org/10.3201/eid1609.091389>.
- Diancourt, L., Passet, V., Verhoef, J., Grimont, P.A., Brisse, S., 2005. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J. Clin. Microbiol.* 43, 4178–4182. <https://doi.org/10.1128/JCM.43.8.4178-4182.2005>.
- Dominguez, J.E., Redondo, L.M., Figueroa Espinosa, R.A., Cejas, D., Gutkind, G.O., Chacana, P.A., Di Conza, J.A., Fernandez Miyakawa, M.E., 2018. Simultaneous carriage of mcr-1 and other antimicrobial resistance determinants in *Escherichia coli* from poultry. *Front. Microbiol.* 9, 1679. <https://doi.org/10.3389/fmicb.2018.01679>.
- van Duin, D., Doi, Y., 2017. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence*. 8, 460–469. <https://doi.org/10.1080/21505594.2016.1222343>.
- Espinosa, R.F., Rumi, V., Marchisio, M., Cejas, D., Radice, M., Vay, C., Barrios, R., Gutkind, G., Di Conza, J., 2018. Fast and easy detection of CMY-2 in *Escherichia coli* by direct MALDI-TOF mass spectrometry. *J. Microbiol. Methods* 148, 22–28. <https://doi.org/10.1016/j.mimet.2018.04.001>.
- Gaibani, P., Galea, A., Fagioni, M., Ambretti, S., Sambri, V., Landini, M.P., 2016. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of KPC-producing *Klebsiella pneumoniae*. *J. Clin. Microbiol.* 54, 2609–2613. <https://doi.org/10.1128/JCM.01242-16>.
- Giakkoupi, P., Papagiannitsis, C.C., Miriagou, V., Pappa, O., Polemis, M., Tryfinopoulou, K., Tzouveleki, L.S., Vatopoulos, A.C., 2011. An update of the evolving epidemic of bla_{KPC-2}-carrying *Klebsiella pneumoniae* in Greece (2009–10). *J. Antimicrob. Chemother.* 66, 1510–1513. <https://doi.org/10.1093/jac/dkr166>.
- Gutkind, G., Di Conza, J., Power, P., Radice, M., 2013. β-Lactamase-mediated resistance: a biochemical, epidemiological and genetic overview. *Curr. Pharm. Des.* 19, 164–208. <https://doi.org/10.2174/1381612811306020164>.
- Hart, P.J., Wey, E., McHugh, T.D., Balakrishnan, I., Belgacem, O., 2015. A method for the detection of antibiotic resistance markers in clinical strains of *Escherichia coli* using MALDI mass spectrometry. *J. Microbiol. Methods* 111, 1–8. <https://doi.org/10.1016/j.mimet.2015.01.020>.
- Hooff, G.P., van Kampen, J.J., Meesters, R.J., van Belkum, A., Goessens, W.H., Luijck, T.M., 2012. Characterization of beta-lactamase enzyme activity in bacterial lysates using MALDI-mass spectrometry. *J. Proteome Res.* 11, 79–84. <https://doi.org/10.1021/pr200858r>.
- Ketterlinus, R., Hsieh, S.Y., Teng, S.H., Lee, H., Pusch, W., 2005. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. *Biotechniques* 38, 37–40.
- Kitchel, B., Rasheed, J.K., Patel, J.B., Srinivasan, A., Navon-Venezia, S., Carmeli, Y., Brolund, A., Giske, C.G., 2009. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob. Agents Chemother.* 53, 3365–3370. <https://doi.org/10.1128/AAC.00126-09>.
- Kumar, A., Roberts, D., Wood, K.E., Light, B., Parrillo, J.E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., Gurka, D., Kumar, A., Cheang, M., 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit. Care Med.* 34, 1589–1596. <https://doi.org/10.1097/01.CCM.0000217961.75225.E9>.
- Lee, K., Chong, Y., Shin, H.B., Kim, Y.A., Yong, D., Yum, J.H., 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin. Microbiol. Infect.* 7, 88–91. <https://doi.org/10.1046/j.1469-0691.2001.00204.x>.
- Lima-Morales, D., Avila, H., Soldi, T., Dalmolin, T.V., Lutz, L., Aquino, V., Zavascki, A.P., Barth, A.L., 2018. Rapid detection of carbapenemase production directly from blood culture by colorimetric methods: evaluation in a routine microbiology laboratory. *J. Clin. Microbiol.* 56. <https://doi.org/10.1128/JCM.00325-18>.
- Luna, C.M., Aruj, P., Niederman, M.S., Garzon, J., Violi, D., Prignoni, A., Rios, F., Baquero, S., Gando, S., Grupo Argentino de Estudio de la Neumonia Asociada al Respirador, G., 2006. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. *Eur. Respir. J.* 27, 158–164. <https://doi.org/10.1183/09031936.06.00049105>.
- Matsuda, N., Matsuda, M., Notake, S., Yokokawa, H., Kawamura, Y., Hiramatsu, K., Kikuchi, K., 2012. Evaluation of a simple protein extraction method for species identification of clinically relevant staphylococci by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J. Clin. Microbiol.* 50, 3862–3866. <https://doi.org/10.1128/JCM.01512-12>.
- Mirande, C., Canard, I., Buffet Croix Blanche, S., Charrier, J.P., van Belkum, A., Welker, M., Chatellier, S., 2015. Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS. *Eur. J. Clin. Microbiol. Infect. Dis.* 34, 2225–2234. <https://doi.org/10.1007/s10096-015-2473-z>.
- Naas, T., Cuzon, G., Villegas, M.V., Lartigue, M.F., Quinn, J.P., Nordmann, P., 2008. Genetic structures at the origin of acquisition of the beta-lactamase bla_{KPC} gene. *Antimicrob. Agents Chemother.* 52, 1257–1263. <https://doi.org/10.1128/AAC.01451-07>.
- Navon-Venezia, S., Chmelnitsky, I., Leavitt, A., Schwaber, M.J., Schwartz, D., Carmeli, Y., 2006. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant *Escherichia coli* clones in Israel. *Antimicrob. Agents Chemother.* 50, 3098–3101. <https://doi.org/10.1128/AAC.00438-06>.
- Nordmann, P., Gniadkowski, M., Giske, C.G., Poirer, L., Woodford, N., Miriagou, V., European Network on, C., 2012. Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin. Microbiol. Infect.* 18, 432–438. <https://doi.org/10.1111/j.1469-0691.2012.03815.x>.
- Oviano, M., Sparbier, K., Barba, M.J., Kostrzewa, M., Bou, G., 2016. Universal protocol for the rapid automated detection of carbapenem-resistant gram-negative bacilli directly from blood cultures by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS). *Int. J. Antimicrob. Agents* 48, 655–660. <https://doi.org/10.1016/j.ijantimicag.2016.08.024>.
- Papagiannitsis, C.C., Kotsakis, S.D., Tuma, Z., Gniadkowski, M., Miriagou, V., Hrabak, J., 2014. Identification of CMY-2-type cephalosporinases in clinical isolates of Enterobacteriaceae by MALDI-TOF MS. *Antimicrob. Agents Chemother.* 58, 2952–2957. <https://doi.org/10.1128/AAC.02418-13>.
- Partridge, S.R., 2014. Tn4401 carrying bla_{KPC} is inserted within another insertion in pKpQIL and related plasmids. *J. Clin. Microbiol.* 52, 4448–4449. <https://doi.org/10.1128/JCM.02426-14>.
- Rhodes, R.E., Lubans, D.R., Karunamuni, N., Kennedy, S., Plotnikoff, R., 2017. Factors associated with participation in resistance training: a systematic review. *Br. J. Sports Med.* 51, 1466–1472. <https://doi.org/10.1136/bjsports-2016-096950>.
- Ricobono, E., Antonelli, A., Pecile, P., Bogaerts, P., D'Andrea, M.M., Rossolini, G.M., 2018. Evaluation of the KPC K-SeT(R) immunochromatographic assay for the rapid detection of KPC carbapenemase producers from positive blood cultures. *J. Antimicrob. Chemother.* 73, 539–540. <https://doi.org/10.1093/jac/dkx406>.
- Sandalakis, V., Goniatakis, I., Vranakis, I., Chochlakis, D., Psaroulaki, A., 2017. Use of MALDI-TOF mass spectrometry in the battle against bacterial infectious diseases: recent achievements and future perspectives. *Expert Rev. Proteomics*. 14, 253–267. <https://doi.org/10.1080/14789450.2017.1282825>.
- Sparbier, K., Schubert, S., Weller, U., Boogen, C., Kostrzewa, M., 2012. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against beta-lactam antibiotics. *J. Clin. Microbiol.* 50, 927–937. <https://doi.org/10.1128/JCM.05737-11>.
- Stoesser, N., Sheppard, A.E., Peirano, G., Anson, L.W., Pankhurst, L., Sebra, R., Phan, H.T.T., Kasarskis, A., Mathers, A.J., Peto, T.E.A., Bradford, P., Motyl, M.R., Walker, A.S., Crook, D.W., Pitout, J.D., 2017. Genomic epidemiology of global *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Escherichia coli*. *Sci. Rep.* 7, 5917. <https://doi.org/10.1038/s41598-017-06256-2>.
- Tariq, T.M., Rasool, E., 2016. Emerging trends of bloodstream infections: a six-year study at a paediatric tertiary care hospital in Kabul. *J. Coll. Physicians Surg. Pak.* 26, 887–891.
- Tran, A., Alby, K., Kerr, A., Jones, M., Gilligan, P.H., 2015. Cost savings realized by implementation of routine microbiological identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J. Clin. Microbiol.* 53, 2473–2479. <https://doi.org/10.1128/JCM.00833-15>.
- Tsakris, A., Kristo, I., Poulou, A., Themeli-Digalaki, K., Ikonomidis, A., Petropoulou, D., Pourmaras, S., Sofianou, D., 2009. Evaluation of boronic acid disk tests for differentiating KPC-possessing *Klebsiella pneumoniae* isolates in the clinical laboratory. *J. Clin. Microbiol.* 47, 362–367. <https://doi.org/10.1128/JCM.01922-08>.
- Ventola, C.L., 2015. The antibiotic resistance crisis: part 1: causes and threats. *P T.* 40, 277–283.
- Wareham, D.W., Phee, L.M., Abdul Momin, M.H.F., 2018. Direct detection of carbapenem resistance determinants in clinical specimens using immunochromatographic lateral flow devices. *J. Antimicrob. Chemother.* <https://doi.org/10.1093/jac/dky095>.
- Youn, J.H., Drake, S.K., Weingarten, R.A., Frank, K.M., Dekker, J.P., Lau, A.F., 2016. Clinical performance of a matrix-assisted laser desorption ionization-time of flight mass spectrometry method for detection of certain bla_{KPC}-containing plasmids. *J. Clin. Microbiol.* 54, 35–42. <https://doi.org/10.1128/JCM.01643-15>.